ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / CERS
BWAY (47) SSII (30) DCTH (62) SENS (41) ⌘ Pro Terminal →

Cerus Corporation (CERS) — RQD Stock Rating Cockpit

$2.28 -6.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.25

Cerus Corporation (CERS) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $491.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CERS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Cerus Corporation (NASDAQ: CERS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.28 (-6.56% 1D, market cap $491.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CERS ranks #843 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CERS compare to BWAY and SSII in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), CERS carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.5%. By comparison, BWAY (BrainsWay Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $478.7M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M). Among the 5-stock peer group, CERS leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CERS?
▼

Per CERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001020214), Cerus Corporation generated $233.8M in revenue (+16.1% YoY), -$15.6M in net income, and $1.1M in free cash flow against $221.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.25 (-1.37%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (4)Whales (8)SEC (8)Macro (5)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
$4 Bull$2 Base$2 Bear
📬 FREE CERS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CERS)Realized 20D OHLCV Swing Band: ±8%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY CERS SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (27% of score)

20D Institutional Volume Accumulation (±8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
22
Grade E$2.26-1.8% Next Q
Q2 (-2Q)
25
Grade E$2.22+6.8% Next Q
Q3 (-1Q)
27
Grade E$2.37-3.8% Next Q
Current
30
Grade E$2.28-9.6% Hist 90D α
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CERS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CERS currently carries a cautious 30/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.46) and Max Pain ($2.39) forces dealer call-delta covering toward $3.64.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CERS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CERS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
53.930 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
6 / 99-Pt Accounting
52-WEEK LASER RANGE43% OF RANGE
L: $1$2.28H: $3
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 13 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CERS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-15.5% ROIC with 42.0% gross margin and 0.23% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 0.20 and Piotroski 6/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

13/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like CERS
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CERS)

  • ✓Walkthrough of CERS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.18%📐 WEDGE COMPRESSION COIL
2026-11-02O $2.42H $2.44L $2.28C $2.28VOL 1.35M
RES: $2.46SUP: $2.13SMA50: $2.46SMA200: $2.45
$3.59$3.10$2.61$2.13$1.64RES $2.46SUP $2.13$2.282026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CERS Butterfly Map → + Track CERS →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +16.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CERS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CERS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CERS)

Health Care Rank #843 of 1016 ⚔️ BWAY vs CERS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CERS vs. BWAY, SSII, DCTH, SENS)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cerus Corporation (CERS) ranks #843 by composite RQD confidence (30/100, grade E) and #456 by equity capitalization ($491.7M). Within this direct 5-issuer industry benchmark cohort, CERS leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with CERS at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CERS ACTIVE
Cerus Corporation
E 30/100 — — -15.5% -6.56% $491.7M Benchmark Subject
BWAY
BrainsWay Ltd.
D 47/100 — — — -4.78% $478.7M /bway-vs-cers →
SSII
SS Innovations International Inc.
E 30/100 — 46.0% -18.5% -1.26% $477.2M /ssii-vs-cers →
DCTH
Delcath Systems Inc.
C 62/100 — 86.2% 0.8% -4.10% $508.0M /dcth-vs-cers →
SENS
Senseonics Holdings Inc.
D- 41/100 — 44.7% -35.0% -2.46% $515.5M /sens-vs-cers →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001020214

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cerus Corporation (CERS) reported GAAP revenue of $233.8M (+16.1% vs. FY2024 revenue of $201.3M , and +25.2% cumulative change since FY2023) , GAAP net income of -$15.6M, operating cash flow of $4.8M, and free cash flow of $1.1M (-87.0% YoY). On the balance sheet, CERS closed FY2025 with $221.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $233.8M -$15.6M $4.8M $1.1M $221.9M —
FY2024 (FY) 2024-12-31 $201.3M -$20.9M $11.4M $8.5M $200.9M —
FY2023 (FY) 2023-12-31 $186.8M -$37.5M -$43.2M -$43.2M — —

3. CERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Cerus Corporation (NASDAQ: CERS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.28 (-6.56% 1D, market cap $491.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CERS ranks #843 in composite RQD confidence.

How does CERS compare to BWAY and SSII in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CERS carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -15.5%. By comparison, BWAY (BrainsWay Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $478.7M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $477.2M). Among the 5-stock peer group, CERS leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CERS?

Per CERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001020214), Cerus Corporation generated $233.8M in revenue (+16.1% YoY), -$15.6M in net income, and $1.1M in free cash flow against $221.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CERS trading relative to its 50-day, 200-day, and 52-week technical levels?

CERS last traded at $2.28 (-6.56% on volume of 1,503,459 shares), positioning the stock -7.32% below its 50-day simple moving average ($2.46) and -6.94% below its 200-day simple moving average ($2.45). Across its 52-week range of $1.38 to $3.47, CERS sits at the 43.1% percentile with a 14-day RSI of 53.9 (NEUTRAL RANGE) and an implied next-earnings move of ±8.0% ($2.10 to $2.46).

CERS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CERS stock right now?

Cerus Corporation (CERS) currently earns a Roarable Rating of E (Strong Sell — SELL) with 30/100 RQD Confidence. Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.

What is CERS's 12-month price target and RQD AI Jury consensus?

CERS's 12-month base price target is $1.99 (range $1.55 to $3.64), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CERS RQD Cockpit CERS 12M Forecast CERS Earnings & Move CERS Dividends & DRIP CERS Insiders & 13F CERS Whale Options CERS Profit Sankey CERS News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CERS — Cerus Corporation: What the Facts Mean to a Prospective Investor

Engine: Haiku 5.5 Dossier Pipeline
As of: 2026-11-02T14:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Cerus Corporation (CERS) carries a composite score of 30/100 (E — Roarable Strong Sell — Forensic Risk / Avoid) at a current price of $2.28 (-6.56%). Fundamental cash generation scores 4/20 (ROIC -15.5%, FCF yield 0.23%), institutional 13F whale accumulation scores 8/20, insider conviction scores 5/20, macro regime alignment scores 5/20 (Beta 1.00), and forensic balance-sheet protection scores 8/20 (Altman Z-Score 0.20, Piotroski F-Score 6/9).

Investor Implication: At current trailing P/E and current forward P/E within Medical/Dental Instruments, upside depends on sustained operating margin expansion (-3.7%) and free cash flow conversion relative to the 52-week range of $1.38 – $3.47.

Butterfly Effect: Supply-Chain, Sector & Catalyst Ripples

Operating in Medical/Dental Instruments (Health Care), CERS is sensitive to 2nd-order capital expenditure cycles, input cost spreads (gross margin —), and institutional positioning across its peer cohort. Prospective investors should monitor quarterly order backlog conversion, sector capex guidance, and Form 4 insider cluster activity (0 recent filings tracked).

Open Questions to Watch: (1) Margin trajectory vs. peer median; (2) FCF conversion sustainability over the next 4 quarters; (3) Institutional 13F rebalancing around upcoming earnings.

CERS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cerus Corporation (CERS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CERS Debate Forum (3) ↓
🟢 CATALYST Yahoo Finance • 94d ago
Cerus Q2 Earnings Call Highlights

Cerus (NASDAQ:CERS) reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America

Read Full Source ↗
🔴 RISK WATCH Yahoo Finance • 185d ago
Cerus (CERS) Q1 2026 Earnings Transcript

With me on the call are Obi Greenman, Cerus Corporation’s president and chief executive officer; Vivek K. Jayaraman, Cerus Corporation’s chief operating officer, incoming president and chief executive officer; and Kevin

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CERS Bull vs. Bear Conversation Board — What's Your Call at $2.28?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CERS 🐻 67% BEARISH CONVICTION
1. Pick Your Side on CERS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.15 (-11.9%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CERS (E • RQD 30/100) a Buy at $2.44?

Welcome to the CERS (Cerus Corporation) Roar Pit. Current RQD Composite is 30/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.03 (-16.8%)
Spot @ $2.44

Pump the brakes on CERS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CERS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Cerus Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $2.93 (+20.1%)
Spot @ $2.44

CERS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CERS, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $2.44 (52-wk range $1.38 - $3.47), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%